News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Is Vertex (VRTX)'s New CF Drug Unprecedented? Incremental? Expensive? Maybe All Three



3/30/2017 5:54:20 AM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs
Shares in Boston’s Vertex Pharmaceuticals are up 22% to $109 after the biotechnology company released data on an experimental combination pill to treat cystic fibrosis, a genetic disease that shortens patients' lives by affecting their lungs and digestive systems. That gives the biotech a market capitalization of $27 billion.

“To me, this is really unprecedented innovation,” says Jeffrey Leiden, Vertex’s chief executive. Vertex has had 10 positive late-stage trials in cystic fibrosis in five years, and if approved this new medicine will be the third it has brought to market. “To me, that’s an amazing story. It’s one of the things I’m proudest of about the company.”

Read at Forbes


comments powered by Disqus
Forbes
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES